NCT03367377View on ClinicalTrials.gov

A Study of LY3209590 in Participants With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

January 3, 2018

Primary Completion Date

October 3, 2018

Study Completion Date

October 3, 2018

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

LY3209590

Administered SC

DRUG

Insulin Glargine

Administered SC

Trial Locations (3)

27265

High Point Clinical Trials Center, High Point

33143

Miami Research Associates, South Miami

M4G 3E8

LMC Endocrinology Centres Ltd., Toronto

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03367377 - A Study of LY3209590 in Participants With Type 2 Diabetes | Biotech Hunter | Biotech Hunter